Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
Adalimumab(Ahrasin) is a fully human anti-tumor necrosis factor-α(TNF-α) monoclonal antibaby, a biosimilar drug of HUMIRA. Excessive inflammation in a variety of immune-mediated diseases in humans are associated with TNF-α.
Indications:
Rheumatoid Arthritis; Ankylosing spondylitis; Psoriasis; Crohn's disease; Uveitis; Polyarticular juvenile idiopathic arthritis ;Plaque psoriasis in children;Crohn's disease in children
Recommended reading:
Adalimumab Biosimilar: A Promising Alternative to Expensive Biologics
Adalimumab Biosimilars: Advancing Healthcare Access with Kexing Biopharm
Download instructions
Contact us